(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 January 2011 (27.01.2011)

PCT

(10) International Publication Number
WO 2011/011199 A1

(51) International Patent Classification:
A61K 31/4745 (2006.01) *A61K 45/06* (2006.01)
A61K 31/519 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2010/041244

(22) International Filing Date:
7 July 2010 (07.07.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/228,121	23 July 2009 (23.07.2009)	US
61/262,079	17 November 2009 (17.11.2009)	US
12/684,053	7 January 2010 (07.01.2010)	US

(71) Applicant *(for all designated States except US)*: **CYLENE PHARMACEUTICALS, INC.** [US/US]; 5820 Nancy Ridge Drive, Suite 200, San Diego, California 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DRYGIN, Denis** [RU/US]; 14125 Via Alisal, San Diego, California 92128 (US). **ANDERES, Kenna** [US/US]; 5522 Mill Creek Road, San Diego, California 92130 (US). **HO, Caroline B.** [CA/US]; 15540 Sumac Terrace, Valley Center, California 92082 (US). **BLIESATH, Joshua R.** [US/US]; 1306 Scenic Drive, Escondido, California 92029 (US). **PROFFITT, Christopher B.** [US/US]; 12704 Roberto Way, Poway, California 92064 (US). **O'BRIEN, Sean** [GB/US]; 2958 Emerald Place, Carlsbad, California 90029 (US). **RICE, William G.** [US/US]; 13601 Nogales Drive, Del Mar, California 92014 (US).

(74) Agents: **WU, Nan** et al.; Cooley LLP, 777 6th Street, NW, Suite 1100, Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,

[Continued on next page]

(54) Title: COMBINATION THERAPIES WITH CK2 MODULATORS

(57) Abstract: The present application is generally directed to compounds, compositions and methods of combination therapy for the treatment of neoplastic, inflammatory, autoimmune or infectious disorders.




Figure 81

WO 2011/011199 A1

KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*